Nephros Adds New Board Member

River Edge, N.J.-based Nephros Inc., a medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, has appointed Moshe Pinto to its board of directors.

Pinto was recently the CEO of Home Dialysis Plus, now Outset Medical Inc., a Warburg Pincus backed company dedicated to the development and commercialization of a new hemodialysis system, providing an improved experience for patients. Previously, from 2007 through 2010, he was the CEO of Spiracur Inc., a developer of wound healing technologies that Pinto co-founded out of the Stanford University Biodesign Innovation Program. He also worked for Herzog, Fox & Neeman, a law firm based in Israel. He currently serves on the board of directors of Spiracur. Pinto received an MBA from Stanford University in California., an LLM from Universita di Bologna in Italy, an EMLE from the University of Hamburg in Germany, and an LLB in Law from Tel Aviv University in Israel.

“We are very excited to have Moshe join our Board,” said Daron Evans, CEO of Nephros. “Moshe’s hands-on expertise in dialysis equipment development and dialysis economics provides Nephros with an invaluable resource in our efforts to increase adoption of our dialysis ultrafilters and to expand the commercial evaluation of our hemodiafiltration system.”

“The dialysis industry is a unique marketplace whose significant scale and market dynamics provide opportunities for innovative products,” said Pinto. “I look forward helping Nephros achieve its potential to help both patients and service providers.”